Validity of Monoamine Oxidase in Serum for Diagnosis of Liver Cirrhosis: Estimation of Predictive Values, Sensitivities and Specificities

Publisher Website
Google Scholar
Abstract
The validity of monoamine oxidase (EC 1.4.3.4) activity in serum for the diagnosis of fibroproliferative liver disorders was assessed by measuring the specificity, sensitivity and positive and negative predictive values of the enzyme. Enzyme activity was measured in sera of 567 patients including those with biochemically and/or histologically verified nonfibrotic liver diseases (no. = 64), liver fibrosis (n = 45) and liver cirrhosis (n = 51). The fraction of liver cirrhotic subjects with pathologically elevated monoamine oxidase activity (> 630 U/l) was 0.61, whereas only 0.16 of the cases with liver fibrosis and 0.11 of those with nonfibrotic liver diseases had abnormally high enzyme activities. Among the various categories of diseases tested, significantly increased enzyme activities were confined to liver cirrhosis and chronic active hepatitis. For liver cirrhosis, sensitivities and specificities were calculated as functions of various cut-off (critical) values of monoamine oxidase activity in serum and with respect to a reference population of healthy men and noncirrhotic subjects. The predictive value of the positive test result (enzyme activity > 720 U/l) at a prevalence of liver cirrhosis of maximum 0.033 (estimated incidence of chronic liver diseases in West Germany) is 0.68 if tested against healthy persons and < 0.30 if tested against patients with nonliver cirrhotic diseases. Monoamine oxidase is probably not helpful in the early diagnosis of fibroproliferative liver dysfunctions, but may provide a parameter of complications of cirrhosis, e.g., portal-systemic collateral circulation (portal hypertension).